946
Participants
Start Date
June 21, 2017
Primary Completion Date
October 9, 2021
Study Completion Date
February 28, 2022
Saliva collection
For biomarker assessments
Urine collection
For biomarker assessments
Sputum collection
For primary endpoint assessments and other biomarker assessments
Blood Collection
For biomarker and eligibility assessments
PET/CT Scan
Imaging of the lungs to establish disease extent and severity
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol
Treatment-standard of care
Clinical Infectious Diseases Research Initiative (Khayelitsha site), Cape Town
National Institute of Allergy and Infectious Diseases (NIAID)
NIH